Renal Masses

What Does “Renal Mass” Mean?

“Renal” means relating to the kidney. A renal mass is a description from an imaging test, not a final diagnosis. Its significance depends on whether it is solid or cystic, whether it takes up contrast, its fat content, margins, growth and relationship to kidney structures.

Are All Solid Renal Masses Cancer?

No. The chance of malignancy generally increases with tumour size and suspicious imaging features, but small masses include a meaningful proportion of benign or slow-growing tumours. This is why surveillance and biopsy are reasonable for selected patients.

A final tumour type is established by pathology from biopsy or surgery. In selected cases, imaging is sufficiently characteristic to manage safely without immediate tissue diagnosis.

What Symptoms Can a Renal Mass Cause?

Most small renal masses cause no symptoms and are found incidentally. Symptoms are more likely with larger, bleeding, obstructing or advanced tumours but are not specific to cancer.

The historic combination of haematuria, flank pain and a palpable mass is uncommon and often represents later disease. Waiting for all three symptoms would delay many diagnoses.

Who Has a Higher Risk of Kidney Cancer?

Most renal masses are sporadic and are not caused by anything the patient did. The absence of a risk factor does not make a suspicious enhancing mass harmless.

How is a Renal Mass Evaluated?

Why Are Contrast CT or MRI Important?

Renal-mass protocols image the kidneys before and after contrast at specific times. Change in brightness after contrast—enhancement—shows blood supply within a lesion and helps distinguish an enhancing tumour from simple fluid or other benign appearances.

Imaging also assesses:

• Whether the mass grows outwards or lies deep beside collecting-system or hilar vessels.
• Its relationship to the renal artery, renal vein, ureter and surrounding organs.
• Whether tumour extends into the renal vein or inferior vena cava.
• The opposite kidney and total functioning kidney tissue.
• Suspicious lymph nodes or disease elsewhere when cancer risk justifies staging.

MRI is particularly useful when CT findings remain uncertain, iodinated contrast is unsuitable, a cystic mass needs further characterisation or venous involvement requires definition. The radiology and clinical teams weigh contrast benefit against kidney risk rather than avoiding useful imaging automatically.

Will Everyone Need a Renal-Mass Biopsy?

No. Biopsy is most valuable when its result can realistically change management. A clearly resectable mass in a fit patient may proceed directly to surgery, while biopsy can prevent treatment of a benign mass or guide surveillance, ablation and systemic therapy in selected patients.

Biopsy is generally performed before thermal ablation so that benign tissue is not destroyed without a diagnosis and post-treatment surveillance can reflect the tumour type.

How is Treatment Chosen?

The aim is durable cancer control without sacrificing more functioning kidney than necessary. Tumour size alone is not enough; location, complexity, growth, biopsy, kidney function and patient health are combined.

Every option has trade-offs. Surveillance accepts uncertainty and repeat scans; partial nephrectomy is more technically complex; radical nephrectomy removes more kidney tissue; ablation has a higher chance of local retreatment in some settings. Shared decision-making should make these differences explicit.

What Happens During Partial Nephrectomy?

Partial nephrectomy removes the tumour and a small surrounding margin while leaving the rest of the kidney. It may be performed through open, laparoscopic or robot-assisted surgery according to tumour anatomy and expertise.

The renal artery may be temporarily clamped to control bleeding while the tumour is removed and the kidney is reconstructed. The surgeon closes opened blood vessels and, when necessary, the urine-collecting system. Pathology then confirms tumour type, grade and surgical-margin status.

Important risks include:

• Bleeding requiring transfusion, embolisation or rarely conversion to full kidney removal.
• Urine leak from the collecting system, sometimes requiring a stent or drainage.
• Infection, blood clots, injury to nearby organs and general anaesthetic complications.
• Temporary or permanent reduction in kidney function.
• Positive margin or local recurrence requiring surveillance or further treatment.

The safest approach is determined by tumour complexity and team experience—not by the presence of a robot alone.

What Does Active Surveillance Involve?

Active surveillance uses a planned imaging schedule to measure tumour size and growth and reassess the balance between treatment benefit and risk. It is commonly considered for small renal masses, older or frail patients, significant comorbidity or when biopsy suggests indolent biology.

• Baseline high-quality CT or MRI characterisation.
• Earlier repeat imaging to establish whether the mass is growing.
• Longer intervals when findings remain stable, individualised to risk.
• Periodic kidney-function, symptom and general-health review.
• Biopsy when histology would improve confidence or change the surveillance plan.
• Discussion of treatment if growth, imaging, symptoms, biopsy or patient preference changes.

Slow growth does not prove a mass is benign, while short-term stability does not remove the need for follow-up. Conversely, modest growth does not automatically mean metastatic behaviour. The complete pattern guides action.

Who Should Consider Genetic Counselling?

Referral is particularly relevant with:

• Kidney cancer diagnosed at a younger age than expected.
• Multiple tumours in one kidney or tumours affecting both kidneys.
• Several close relatives with kidney cancer.
• Pathology associated with a known hereditary syndrome.
• Personal or family features suggesting VHL, Birt–Hogg–Dubé, HLRCC or another syndrome.

A hereditary diagnosis can change the threshold for intervention, choice of nephron-sparing strategy, surveillance of both kidneys and screening for other syndrome-related conditions. It can also guide relatives.

How is Kidney Function Protected?

• Record baseline creatinine, eGFR, urine protein and blood pressure.
• Preserve kidney tissue through partial nephrectomy when oncologically and technically appropriate.
• Optimise diabetes, hypertension, smoking, weight and cardiovascular risk.
• Avoid unnecessary regular use of kidney-harming medicines and disclose all supplements.
• Coordinate nephrology care for significant CKD, proteinuria, solitary kidney or expected major loss of function.
• Monitor kidney function after surgery, ablation and contrast imaging according to risk.

Most people can live well with one healthy kidney, but removing a kidney reduces renal reserve. The condition of the opposite kidney and the patient's lifetime risk of diabetes, hypertension and CKD matter before surgery.

What Follow-up is Needed?

Follow-up is matched to pathology, tumour extent, treatment and general health. It monitors complications, kidney function, the treated site, the opposite kidney and possible disease recurrence.

• Clinical review for symptoms, blood pressure, recovery and treatment effects.
• Kidney-function blood tests and urine protein when appropriate.
• Abdominal CT, MRI or ultrasound according to recurrence risk and treatment type.
• Chest imaging when clinically indicated by cancer risk.
• Longer surveillance for selected tumours because RCC can occasionally recur late.
• Cardiovascular and CKD prevention after loss of kidney tissue.

Report new haematuria, persistent cough, unexplained weight loss, bone pain, neurological symptoms or flank discomfort between scheduled visits rather than waiting for the next scan.

Myth vs Fact